Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide plus GnRH agonist in AR-positive salivary gland carcinoma
jRCT2080225153Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apalutamide in salivary gland cancer (SGC), sponsored by Janssen Pharmaceutical. Started Apr 2020; status: completed.
02
Drugs
apalutamide
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on jRCT2080225153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225153.